A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
文献类型：期刊论文
| 作者 | Peng, Jie2,3; Zou, Dan3; Han, Lijie1; Yin, Zuomin2; Hu, Xiao2 |
| 刊名 | FRONTIERS IN IMMUNOLOGY
 |
| 出版日期 | 2021-12-15 |
| 卷号 | 12 |
| 关键词 | non-small cell lung cancer support vector machine major pathological response liquid immune profiling neoadjuvant treatment |
| ISSN号 | 1664-3224 |
| DOI | 10.3389/fimmu.2021.778276 |
| 通讯作者 | Peng, Jie(sank44@sina.com) |
| 英文摘要 | The biomarkers for the pathological response of neoadjuvant chemotherapy plus anti-programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) (CAPD) are unclear in non-small cell lung cancer (NSCLC). Two hundred and eleven patients with stage Ib-IIIa NSCLC undergoing CAPD prior to surgical resection were enrolled, and 11 immune cell subsets in peripheral blood were prospectively analyzed using multicolor flow cytometry. Immune cell subtypes were selected by recursive feature elimination and least absolute shrinkage and selection operator methods. The support vector machine (SVM) was used to build a model. Multivariate analysis for major pathological response (MPR) was also performed. Finally, five immune cell subtypes were identified and an SVM based on liquid immune profiling (LIP-SVM) was developed. The LIP-SVM model achieved high accuracies in discovery and validation sets (AUC = 0.886, 95% CI: 0.823-0.949, P < 0.001; AUC = 0.874, 95% CI: 0.791-0.958, P < 0.001, respectively). Multivariate analysis revealed that age, radiological response, and LIP-SVM were independent factors for MPR in the two sets (each P < 0.05). The integration of LIP-SVM, clinical factors, and radiological response showed significantly high accuracies for predicting MPR in discovery and validation sets (AUC = 0.951, 95% CI: 0.916-0.986, P < 0.001; AUC = 0.943, 95% CI: 0.912-0.993, P < 0.001, respectively). Based on immune cell profiling of peripheral blood, our study developed a predictive model for the MPR of patients with NSCLC undergoing CAPD treatment that can potentially guide clinical therapy. |
| WOS关键词 | METASTATIC NONSQUAMOUS NSCLC ; SPECIFIED FINAL ANALYSIS ; TUMOR MUTATIONAL BURDEN ; PEMBROLIZUMAB ; PLATINUM ; LYMPHOCYTES ; EXPRESSION ; EFFICACY |
| 资助项目 | Qian Dong Nan Science and Technology Program[qdnkhJz2020-013] ; Science and Technology Foundation of Guizhou Province[Qian ke he ji chu-ZK 2021] ; Science and Technology Foundation of Guizhou Province[yi ban 454] ; Science and Technology Fund Project of Guizhou Provincial Health Commission[gzwjkj2019-1-077] |
| WOS研究方向 | Immunology |
| 语种 | 英语 |
| WOS记录号 | WOS:000738681800001 |
| 出版者 | FRONTIERS MEDIA SA |
| 资助机构 | Qian Dong Nan Science and Technology Program ; Science and Technology Foundation of Guizhou Province ; Science and Technology Fund Project of Guizhou Provincial Health Commission |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/127205]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Peng, Jie |
| 作者单位 | 1.Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China 3.Guizhou Med Univ, Affiliated Hosp 2, Dept Oncol, Kaili, Peoples R China |
| 推荐引用方式 GB/T 7714 | Peng, Jie,Zou, Dan,Han, Lijie,et al. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer[J]. FRONTIERS IN IMMUNOLOGY,2021,12. |
| APA | Peng, Jie,Zou, Dan,Han, Lijie,Yin, Zuomin,&Hu, Xiao.(2021).A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.FRONTIERS IN IMMUNOLOGY,12. |
| MLA | Peng, Jie,et al."A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer".FRONTIERS IN IMMUNOLOGY 12(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。